T-MAXIMUM

Explore the latest insights on T-MAXIMUM and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of T-MAXIMUM’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Insilico Medicine Nominates ISM9546 as Preclinical Candidate – Oral, Peripherally Restricted VAV1 Molecular Glue Degrader Targets IBD and Rheumatoid Arthritis
CompanyR&D

Insilico Medicine Nominates ISM9546 as Preclinical Candidate – Oral, Peripherally Restricted VAV1 Molecular Glue Degrader Targets IBD and Rheumatoid Arthritis

Insilico Medicine (HKG: 3696), an AI‑powered drug discovery company, announced the nomination of ISM9546 as a preclinical candidate (PCC) – an innovative, oral, peripherally restricted VAV1 molecular glue degrader with…

Lepu Scientech's MemoCarna Oxide Film Single‑Rivet PFO Occluder Approved for Market Launch by NMPA – Novel Design Targets Residual Shunts in Patent Foramen Ovale Closure

Lepu Scientech’s MemoCarna Oxide Film Single‑Rivet PFO Occluder Approved for Market Launch by NMPA – Novel Design Targets Residual Shunts in Patent Foramen Ovale Closure

Luzhu Biotech’s Self‑Developed Recombinant RSV Vaccine Candidate Approved for Clinical Trials by NMPA – Pre‑F Protein Antigen Advances Toward Prevention of RSV Lower Respiratory Tract Disease

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
T-MAXIMUM's MT027 Wins FDA Clearance for Phase 2 Study – Non‑Viral Allogeneic B7‑H3 CAR‑T Targets Advanced Solid Tumor Brain Metastases
CompanyDrug

T-MAXIMUM’s MT027 Wins FDA Clearance for Phase 2 Study – Non‑Viral Allogeneic B7‑H3 CAR‑T Targets Advanced Solid Tumor Brain Metastases